Makers say early tests of the experimental drug indicate it may “break the chain” of rising coronavirus infections.
The makers of an experimental drug, now being trialled by the NHS, say it is 100 per cent effective in protecting against symptomatic cases of the virus.
US-based Regeneron Pharmaceuticals says its two-antibody cocktail called REGEN-COV also reduces overall coronavirus infection rates by about 50 per cent.
The claims are based on interim results and the “confirmatory stage” of the trial will not be complete until the second quarter of this year, but the company has said it is hopeful it may “break the chain” of rising infections.
“The REGEN-COV antibody cocktail may be able to help break this chain by providing immediate passive immunity to those at high risk of infection, in contrast to active vaccines which take weeks to provide protection,” he added.